Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705750 | 0.83 | ERN1 (0.65) | ERN1PIM1 | |
| SCHEMBL14031706 | 0.82 | ERN1 (0.58) | ERN1PIM1 | |
| SCHEMBL2921662 | 0.78 | ERN1 (0.54) | ERN1 | |
| SCHEMBL26857676 | 0.78 | ERN1 (0.54) | ERN1PIM1 | |
| SCHEMBL13623366 | 0.77 | ERN1 (0.58) | ERN1PIM1 | |
| SCHEMBL5419403 | 0.77 | ERN1 (0.52) | ERN1PIM1 | |
| SCHEMBL27534859 | 0.74 | ERN1 (0.60) | ERN1PIM1 | |
| SCHEMBL29628535 | 0.74 | ERN1 (0.59) | ERN1 | |
| SCHEMBL20607316 | 0.74 | ERN1 (0.59) | ERN1 | |
| SCHEMBL27396923 | 0.74 | ERN1 (0.48) | ERN1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-7078541-B2 | Benzofuran derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1472241-A4 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005027900-A1 | BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1472241-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063975-A1 | Benzofuran derivatives | EDISON PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| WO-2003066618-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063975-A1 | Benzofuran derivatives | NDUFAB1, AIFM1, NDUFAF1 | ERN1 3857/4885PIM1 3275/4885ACHE 3134/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | ERN1 2616/4885PIM1 1484/4885ACHE 289/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ERN1 2730/4885PIM1 2299/4885ACHE 656/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ERN1 2730/4885PIM1 2299/4885ACHE 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.